Clinical Advances in Diagnosis and Personalized Treatments of Chronic Kidney Diseases

Dear Colleagues,

In recent years, there have been significant advances in the diagnosis and personalized treatment of chronic kidney diseases (CKD). Researchers have identified several biomarkers of kidney damage or kidney function that are useful in the early detection and diagnosis of CKD.

In addition, genetic testing has become increasingly important in understanding the underlying causes of CKD. Genetic mutations can predispose individuals to certain types of CKD, and identifying these mutations can help in personalized treatment planning and prognosis assessment.

Advances in genomic medicine and precision medicine have led to personalized treatment approaches for CKD. By analyzing individual genetic profiles and other clinical data, healthcare providers can tailor the treatment plans to the specific needs of each patient, potentially improving the outcomes and inhibiting adverse effects.

Several new pharmacological agents have been developed for the treatment of CKD, targeting various pathways involved in pathogenesis. These therapies offer new options for patients with CKD, especially those who are resistant to the traditional treatments.

Telemedicine and remote monitoring technologies have become increasingly important in the management of CKD, especially in remote or underserved areas. These technologies allow healthcare providers to monitor patients' kidney function, blood pressure, and other relevant parameters remotely, enabling timely intervention and reducing the need for frequent hospital visits.

Nutritional interventions play a crucial role in the management of CKD, and there have been advancements in understanding the role of diet in CKD progression. Personalized dietary plans can help slow disease progression and improve outcomes for patients with CKD.

Finally, regenerative medicine approaches, including stem cell therapy and tissue engineering, hold promise for the treatment of CKD. These therapies aim to repair or replace damaged kidney tissue and restore kidney function. While it is still in the early stages of development, regenerative medicine offers potential long-term solutions for patients with CKD.

Overall, these advancements in diagnosis and personalized treatment have the potential to improve the outcomes and quality of life of patients with CKD. However, further research and clinical trials are needed to fully understand the efficacy and safety of these interventions and to optimize their implementation in clinical practice.

We invite researchers to contribute original articles and review articles that offer insight into clinical advances in diagnosis and personalized treatments of CKD. The potential topics include, but are not limited to the following:

• Biomarkers for early diagnosis;
• Genetic testing;
• Precision medicine approaches;
• Novel therapies;
• Telemedicine and remote monitoring;
• Nutritional interventions;
• Regenerative medicine.

Dr. Claudia Torino
Dr. Vincenzo Antonio Panuccio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• biomarkers for early diagnosis
• genetic testing
• precision medicine approaches
• novel therapies
• telemedicine and remote monitoring
• nutritional interventions
• regenerative medicine